Skip to main content

Correction of press release from 27 November 2020 regarding publication of final terms for the rights issue

The correction refers to the second last sentence of the first paragraph under the heading “Terms for the Rights Issue”. The sentence should rightfully have the wording following below, which was included in the decision by the board of directors on the rights issue, as published on 10 November 2020. This means that the words “70 per cent of” by mistake were omitted in the press release from 27 November 2020.

Two (2) warrants entitle to subscription of one (1) ordinary share in the Company during the period 16 March 2022 up to and including 29 March 2022 at a subscription price which is the higher of (i) SEK 6.47 (the subscription price in the Rights Issue), and (ii) 70 per cent of the volume weighted average price for the Company’s share on Nasdaq Stockholm during the period 28 February 2022 up to and including 11 March 2022.

The press release has been adjusted.

For additional information, please contact:
Anna Ljung, CEO, Phone: + 46 70 766 60 30, e-mail:

Mark Beveridge, VP Finance, Phone: + 46 76 805 82 88, e-mail:

About Moberg Pharma,
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis, with recently completed phase 3 trials in more than 800 patients. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis, intended to be spun off in the separate company OncoZenge. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of Nasdaq Stockholm (OMX: MOB).